FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303684618> ?p ?o ?g. }

• W4303684618 endingPage "15" @default.
• W4303684618 startingPage "8" @default.
• W4303684618 abstract "Recently, a clinical trial (NCT02603432) showed that avelumab maintenance treatment, post first-line chemotherapy, can significantly prolong the overall survival of patients with advanced urothelial carcinoma (UC), however, the treatment was very expensive. This study aimed to determine the cost-effectiveness of avelumab maintenance therapy in advanced or metastatic UC from the US taxpayer perspective.Based on the data of the JAVELIN Bladder 100 clinical trial (NCT02603432), a Markov multi-state model was constructed to investigate the costs and clinical outcomes of avelumab maintenance after platinum-based chemotherapy versus best supportive care (BSC) for advanced or metastatic UC. Parameters of the model came from the 2020 Average Sales Price Drug Pricing Files and published literature. The main outputs were costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Robustness was tested by deterministic and probabilistic sensitivity analyses. The analysis was stratified to include both the overall population and a subset of programmed death-ligand 1 (PD-L1)-positive patients.Avelumab maintenance therapy was estimated to generate an additional 0.26 QALYs (1.46 vs. 1.20 QALYs) and costs $183,271 ($278,323 vs. $95,052) more compared to BSC alone in the overall population, yielding an ICER of $699,065/QALY. For the PD-L1-positive population, avelumab produced a 0.42 increase in QALYs (1.74 vs. 1.32 QALYs) and raised costs to $223,238 ($320,355 vs. $97,117), resulting in an ICER of $521,850/QALY for this population. Both ICERs were above the willingness-to-pay (WTP) threshold of $200,000/QALY. Sensitivity analyses manifested that the model was robust.From the perspective of the US taxpayer, avelumab maintenance therapy is considered cost-ineffective for patients with advanced or metastatic UC at a WTP threshold of $200,000/QALY in the overall population as well as in PD-L1-positive population." @default.
• W4303684618 created "2022-10-09" @default.
• W4303684618 creator A5002995123 @default.
• W4303684618 creator A5011615604 @default.
• W4303684618 creator A5017453632 @default.
• W4303684618 creator A5020232250 @default.
• W4303684618 creator A5028928110 @default.
• W4303684618 creator A5031465004 @default.
• W4303684618 creator A5038750910 @default.
• W4303684618 creator A5039898780 @default.
• W4303684618 creator A5042804899 @default.
• W4303684618 creator A5059392900 @default.
• W4303684618 date "2023-02-01" @default.
• W4303684618 modified "2023-10-01" @default.
• W4303684618 title "Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma–A Cost-Effectiveness Analysis" @default.
• W4303684618 cites W1982967337 @default.
• W4303684618 cites W2005295931 @default.
• W4303684618 cites W2035297454 @default.
• W4303684618 cites W2058056848 @default.
• W4303684618 cites W2144532729 @default.
• W4303684618 cites W2151488185 @default.
• W4303684618 cites W2377410957 @default.
• W4303684618 cites W2516652195 @default.
• W4303684618 cites W2571994217 @default.
• W4303684618 cites W2771737095 @default.
• W4303684618 cites W2806532569 @default.
• W4303684618 cites W2890318130 @default.
• W4303684618 cites W2890398072 @default.
• W4303684618 cites W2893335845 @default.
• W4303684618 cites W2895193853 @default.
• W4303684618 cites W2905414330 @default.
• W4303684618 cites W2959432976 @default.
• W4303684618 cites W2964014383 @default.
• W4303684618 cites W2970590492 @default.
• W4303684618 cites W2973437854 @default.
• W4303684618 cites W2976156055 @default.
• W4303684618 cites W2983476233 @default.
• W4303684618 cites W2986683807 @default.
• W4303684618 cites W2996637695 @default.
• W4303684618 cites W3023072291 @default.
• W4303684618 cites W3023288864 @default.
• W4303684618 cites W3036255811 @default.
• W4303684618 cites W3043071933 @default.
• W4303684618 cites W3044459469 @default.
• W4303684618 cites W3082331336 @default.
• W4303684618 cites W3087464965 @default.
• W4303684618 cites W3092564101 @default.
• W4303684618 cites W3112465583 @default.
• W4303684618 cites W3127964968 @default.
• W4303684618 cites W4242669880 @default.
• W4303684618 doi "https://doi.org/10.1016/j.clgc.2022.10.001" @default.
• W4303684618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328903" @default.
• W4303684618 hasPublicationYear "2023" @default.
• W4303684618 type Work @default.
• W4303684618 citedByCount "1" @default.
• W4303684618 countsByYear W43036846182023 @default.
• W4303684618 crossrefType "journal-article" @default.
• W4303684618 hasAuthorship W4303684618A5002995123 @default.
• W4303684618 hasAuthorship W4303684618A5011615604 @default.
• W4303684618 hasAuthorship W4303684618A5017453632 @default.
• W4303684618 hasAuthorship W4303684618A5020232250 @default.
• W4303684618 hasAuthorship W4303684618A5028928110 @default.
• W4303684618 hasAuthorship W4303684618A5031465004 @default.
• W4303684618 hasAuthorship W4303684618A5038750910 @default.
• W4303684618 hasAuthorship W4303684618A5039898780 @default.
• W4303684618 hasAuthorship W4303684618A5042804899 @default.
• W4303684618 hasAuthorship W4303684618A5059392900 @default.
• W4303684618 hasConcept C112930515 @default.
• W4303684618 hasConcept C121608353 @default.
• W4303684618 hasConcept C126322002 @default.
• W4303684618 hasConcept C143998085 @default.
• W4303684618 hasConcept C207103383 @default.
• W4303684618 hasConcept C2776694085 @default.
• W4303684618 hasConcept C2777381376 @default.
• W4303684618 hasConcept C2777701055 @default.
• W4303684618 hasConcept C2778283404 @default.
• W4303684618 hasConcept C2780057760 @default.
• W4303684618 hasConcept C2780352672 @default.
• W4303684618 hasConcept C2908647359 @default.
• W4303684618 hasConcept C2911057145 @default.
• W4303684618 hasConcept C3019080777 @default.
• W4303684618 hasConcept C3019882237 @default.
• W4303684618 hasConcept C44249647 @default.
• W4303684618 hasConcept C71924100 @default.
• W4303684618 hasConcept C99454951 @default.
• W4303684618 hasConceptScore W4303684618C112930515 @default.
• W4303684618 hasConceptScore W4303684618C121608353 @default.
• W4303684618 hasConceptScore W4303684618C126322002 @default.
• W4303684618 hasConceptScore W4303684618C143998085 @default.
• W4303684618 hasConceptScore W4303684618C207103383 @default.
• W4303684618 hasConceptScore W4303684618C2776694085 @default.
• W4303684618 hasConceptScore W4303684618C2777381376 @default.
• W4303684618 hasConceptScore W4303684618C2777701055 @default.
• W4303684618 hasConceptScore W4303684618C2778283404 @default.
• W4303684618 hasConceptScore W4303684618C2780057760 @default.
• W4303684618 hasConceptScore W4303684618C2780352672 @default.
• W4303684618 hasConceptScore W4303684618C2908647359 @default.
• W4303684618 hasConceptScore W4303684618C2911057145 @default.

• next